SCHEDULE 13D/A: Caligan Partners Amends Anika Therapeutics Stake Disclosure
Schedule 13D Amendment
Caligan Partners LP updated its Schedule 13D filing for Anika Therapeutics, Inc., detailing derivative agreements representing 4.3% economic exposure.
Summary
- Caligan Partners LP and David Johnson filed Amendment No. 5 to their Schedule 13D regarding Anika Therapeutics, Inc.
- The amendment specifically updates Item 6, detailing derivative agreements.
- Caligan Fund and Caligan Accounts have entered into cash-settled swap agreements referencing 623,621 shares of Anika Therapeutics Common Stock.
- These derivative agreements provide economic exposure comparable to 4.3% of the Issuer's Common Stock.
- The derivative agreements do not grant voting or dispositive power over the referenced shares.
- The Reporting Persons disclaim beneficial ownership of these derivative-referenced shares.
- Caligan Partners LP and David Johnson continue to beneficially own 1,435,130 shares, representing 9.95% of the class, with shared voting and dispositive power.
Sentiment
Score: 5
Explanation: The filing is a routine amendment to a Schedule 13D, primarily clarifying the nature of derivative holdings. It does not contain information that would inherently be positive or negative for the company's operational performance or financial health.
Industry Context
This filing reflects an investor's ongoing position and strategy in a publicly traded biotechnology or medical technology company (Anika Therapeutics). It highlights the use of derivatives by activist or significant investors to gain economic exposure without direct voting control, a common practice in financial markets.
Stakeholder Impact
- Shareholders: Provides transparency regarding the economic exposure and beneficial ownership structure of a significant investor, Caligan Partners LP, which may influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2023-08-17 | Original Schedule 13D filing date |
| 2026-01-23 | Date of event requiring Amendment No. 5 filing |
| 2026-01-27 | Signature date of Amendment No. 5 |
Keywords
Anika Therapeutics, Caligan Partners, Schedule 13D, beneficial ownership, common stock, derivative agreements, cash settled swaps, equity stake, investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.